Exposure-Response Modeling to Support Dosing Selection for Phase IIb Development of Kukoamine B in Sepsis Patients

Aim: Kukoamine B, a small molecule compound, is being developed for the treatment of sepsis in a Phase II clinical trial. The objective of this study was to optimize dosing selection for a Phase IIb clinical trial using an exposure-response model. Methods: Data of 34 sepsis patients from a Phase IIa...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Huanhuan, Hu, Xiaoyun, Wang, Teng, Cui, Cheng, Jiang, Ji, Dong, Kai, Chen, Shuai, Jin, Chunyan, Zhao, Qian, Du, Bin, Hu, Pei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8091127/
https://www.ncbi.nlm.nih.gov/pubmed/33953679
http://dx.doi.org/10.3389/fphar.2021.645130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8091127/
https://www.ncbi.nlm.nih.gov/pubmed/33953679
http://dx.doi.org/10.3389/fphar.2021.645130

Ejemplares similares